Drug · CHEMBL85
RISPERIDONE
7 sourcespipelines-2026-09-18-0.3.1
Cite this record
ConductScience Library. RISPERIDONE. Drugs and targets, record CHEMBL85. Release pipelines-2026-09-18-0.3.1, 18 Sept 2026. https://conductscience.org/library/drugs/CHEMBL85
On this page
Drug
Names and IDs as ChEMBL gives them, through Open Targets.
- Brand names
- Okedi, Perseris kit, Risperdal, Risperdal consta, Risperdal consta long acting, Risperdal m, Risperdal m-tab, Risperdal quicklet, Risvan, Rykindo, Uzedy
- ChEMBL
- Other names
- LY-03004, LY03004, N05AX08, NSC-759895, Perseris, R 64 766, R-64,766, R-64-766, R-64766, RCN-3028, RCN3028, Risperidona, Risvan, Rykindo, Uzedy
- ChEMBL
- Open Targets' highest stage
- Approval, for 6 of its 57 diseases, from ATC, DailyMed, EMA Human Drugs, PMDA and TTD
- Open Targets
Targets3
The targets ChEMBL's mechanism records give for the drug, through Open Targets. A mechanism record says what the drug acts on, not how strongly.
| Target | Protein | Mechanism | Action | Gene in Genes |
|---|---|---|---|---|
| DRD2 | D(2) dopamine receptor | Dopamine D2 receptor antagonist | ANTAGONIST | https://conductscience.org/library/genes/1813 |
| HTR2A | 5-hydroxytryptamine receptor 2A | Serotonin 2a (5-HT2a) receptor antagonist | ANTAGONIST | https://conductscience.org/library/genes/3356 |
| HTR2C | 5-hydroxytryptamine receptor 2C | Serotonin 2c (5-HT2c) receptor antagonist | ANTAGONIST | https://conductscience.org/library/genes/3358 |
Source ChEMBL
Diseases57
The diseases Open Targets' clinical reports study the drug for, the most trial reports first. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
1 to 10 of 57Source Open Targets
See all 57 diseasesTrials457
Trials whose record names the drug by a name ChEMBL states, posted results first, then the largest. Open Targets read each trial's text to find its drugs. 1 more that Open Targets linked to it is not shown, since the release's checks do not confirm it.
| Trial | Title | Phase | Participants | Results first posted | Named as | Linked by | Source |
|---|---|---|---|---|---|---|---|
| NCT00856583 | Safety Study of Sertindole Versus Risperidone Under Normal Conditions of Use | Phase 3 | 9,809 | 2011-08-01 | risperidone | Its name | ClinicalTrials.gov |
| NCT00589914 | Comparison of Paliperidone Palmitate and RISPERDAL CONSTA in Patients With Schizophrenia | Phase 3 | 1,221 | 2011-10-04 | risperidone | Its name | ClinicalTrials.gov |
| NCT00206102 | A Study of the Cataractogenic Potential of Seroquel and Risperdal in the Treatment of Participants With Schizophrenia or Schizoaffective Disorder | Phase 4 | 1,098 | 2011-07-13 | risperidone | Its name | ClinicalTrials.gov |
| NCT00600756 | Comparison of the Subjective Well-being and Tolerability of Quetiapine XR to Risperidone | Phase 3 | 798 | 2012-09-12 | risperidone | Its name | ClinicalTrials.gov |
| NCT00216476 | A Study of Relapse Prevention and the Effectiveness of Long-acting Injectable Risperidone and Quetiapine Tablets in the Treatment of Patients With Schizophrenia or Schizoaffective Disorder | Phase 3 | 753 | 2010-08-10 | risperidone | Its name | ClinicalTrials.gov |
| NCT00694707 | Safety and Efficacy of Cariprazine (RGH-188) in the Acute Exacerbation of Schizophrenia | Phase 2 | 732 | 2019-06-12 | risperidone | Its name | ClinicalTrials.gov |
| NCT02469155 | A Trial to Assess the Antipsychotic Efficacy of ITI-007 Over 6 Weeks of Treatment | Phase 3 | 696 | 2025-10-02 | risperidone | Its name | ClinicalTrials.gov |
| NCT00641745 | Lurasidone HCl - A Long Term Safety Phase 3 Study of Patients With Clinically Stable Schizophrenia | Phase 3 | 629 | 2011-10-06 | risperidone | Its name | ClinicalTrials.gov |
| NCT00337662 | Efficacy Study of Early Onset of Antipsychotic Drug Action in Schizophrenia | Phase 4 | 628 | 2009-08-04 | risperidone | Its name | ClinicalTrials.gov |
| NCT00391222 | A Study to Evaluate the Efficacy and Safety of Risperidone for the Prevention of Mood Episodes in the Treatment of Patients With Bipolar I Disorder | Phase 3 | 585 | 2010-11-01 | risperidone | Its name | ClinicalTrials.gov |
1 to 10 of 457
See all 457 trialsComparisons in its trials108
Comparisons Trial comparisons calculated in the trials whose record names the drug, most participants first. A comparison in one of its trials does not always compare the drug, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Sertindole vs Risperidone: Number of Participants With Suicide Attempts (Fatal and Non-fatal) - MedDRA | 43 of 4,905 | 65 of 4,904 | 9,809 | NCT00856583 | Trial comparisons |
| Sertindole vs Risperidone: Cause-specific Mortality: Number of Participants With Cardiac Deaths - MedDRA | 17 of 4,905 | 8 of 4,904 | 9,809 | NCT00856583 | Trial comparisons |
| Sertindole vs Risperidone: Cause-specific Mortality: Number of Participants With Cardiac Deaths - ISC | 31 of 4,905 | 12 of 4,904 | 9,809 | NCT00856583 | Trial comparisons |
| Sertindole vs Risperidone: Cause-specific Mortality: Number of Participants With Completed Suicides - MedDRA | 13 of 4,905 | 21 of 4,904 | 9,809 | NCT00856583 | Trial comparisons |
| Sertindole vs Risperidone: Number of Participants With Suicide Attempts (Fatal and Non-fatal) - ISC | 68 of 4,905 | 76 of 4,904 | 9,809 | NCT00856583 | Trial comparisons |
| Sertindole vs Risperidone: Cause-specific Mortality: Number of Participants With Other Than Cardiac Deaths and Completed Suicides - MedDRA | 34 of 4,905 | 32 of 4,904 | 9,809 | NCT00856583 | Trial comparisons |
| Sertindole vs Risperidone: Number of Participants With Discontinuation of Treatment for Any Reason Other Than Study Closure | 3,136 of 4,905 | 2,597 of 4,904 | 9,809 | NCT00856583 | Trial comparisons |
| Sertindole vs Risperidone: Number of Participants With Hospitalisations, Excluding Hospitalisations Related to the Primary Psychiatric Disease | 174 of 4,905 | 149 of 4,904 | 9,809 | NCT00856583 | Trial comparisons |
| Sertindole vs Risperidone: Second Primary Outcome: Number of Participants With Cardiac Events, Including Arrhythmias, Requiring Hospitalisation | 10 of 4,905 | 6 of 4,904 | 9,809 | NCT00856583 | Trial comparisons |
| Sertindole vs Risperidone: Cause-specific Mortality: Number of Participants With Other Than Cardiac Deaths and Completed Suicides - ISC | 19 of 4,905 | 28 of 4,904 | 9,809 | NCT00856583 | Trial comparisons |
1 to 10 of 108
See all 108 comparisons in its trialsPapers from its trials449
The papers the trials whose record names the drug list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Tests in its trials27
The tests ConductCognition runs that the trials whose record names the drug name in their registered outcomes, as ScienceGraph matched them. ConductCognition's list names the tests it runs, not every test a trial used.
| Test | Trials naming it as an outcome | As a primary outcome | Source |
|---|---|---|---|
| Trail Making Test A | 6 | 2 | ConductCognition |
| Verbal Fluency | 6 | 2 | ConductCognition |
| Verbal Learning | 6 | 3 | ConductCognition |
| Continuous Performance Test | 5 | 3 | ConductCognition |
| Card Sorting Test (Berg) | 4 | 0 | ConductCognition |
| Stroop Color-Word Test | 4 | 1 | ConductCognition |
| Trail Making Test B | 4 | 0 | ConductCognition |
| Digit Span Test | 3 | 0 | ConductCognition |
| Letter-Number Sequencing Task | 3 | 1 | ConductCognition |
| Complex Figure Copy and Recall | 2 | 0 | ConductCognition |
1 to 10 of 27
See all 27 tests in its trialsData dates
The date of each source this release read.
Sources 7
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ConductCognition's list of its testsOur own data
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ConductCognition's list of its testsOur own data: ConductCognition's list of its tests, https://conductcognition.com
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this drug from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/drugs/v1/CHEMBL85
GET https://conductscience.org/api/drugs/v1/CHEMBL85/diseases?page=2